CCC München - Comprehensive Cancer Center München

What CCC München - Comprehensive Cancer Center München does

CCC München (Comprehensive Cancer Center München) is a publicly funded, non-profit oncology center of excellence jointly operated by LMU Klinikum, TUM Klinikum Rechts der Isar, and the Tumorzentrum München. Founded in 2014 and designated as one of 14 German Oncological Centers of Excellence (Onkologische Spitzenzentren) by Deutsche Krebshilfe, it coordinates interdisciplinary cancer care, translational research, and physician training across both Munich university hospital systems, with services extending into Bavaria via the BZKF network (six university hospitals) and nationally via nNGM (lung cancer genomics across 20 centers) and DNPM (personalized medicine across 26 university clinics).

The center's core technical platform combines a Molecular Tumor Board (Molekulares Tumorboard) — which uses next-generation sequencing (NGS) and the §64e SGB V genome sequencing pilot to match advanced-cancer patients to targeted therapies — with a digital video-conferencing infrastructure that connects external referring physicians to specialist consultation. Supporting programs include the SERIO immuno-oncology adverse-event registry (1,832+ cases across 27 centers in 6 countries), an Interdisciplinary ToxBoard for checkpoint inhibitor toxicity, and a patient-facing stack comprising the Patientenhaus (free counseling center), Infoportal Krebs (online information platform with ~60,000 monthly visitors), and the OnkoTalk podcast.

CCC München does not operate a commercial revenue model. Income flows from Deutsche Krebshilfe grants (including continuation funding reaffirmed in 2018), statutory and private health insurance reimbursements for clinical services delivered through the parent hospitals, the §64e SGB V statutory insurance-funded genome sequencing pilot, BMBF/DKTK translational research funding, and donations. Patient acquisition is community-led, driven by physician referrals, tumor board consultations, and clinical trial enrollment rather than marketing.

Name

CCC München - Comprehensive Cancer Center München

Legal name

CCC München - Comprehensive Cancer Center München (Comprehensive Cancer Center München, eine Einrichtung des LMU Klinikums)

Website

https://ccc-muenchen.de

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

CCC München is a publicly funded oncology center of excellence jointly run by LMU and TUM university hospitals in Munich, designated by Deutsche Krebshilfe. It coordinates molecular tumor boards, genomic diagnostics, and research networks serving advanced-cancer patients and referring physicians across Bavaria and Germany.

Ownership category

akta.pro rank

Product category

Comprehensive Cancer Center / Oncology Services

NAICS

General Medical and Surgical Hospitals (622110), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

Services-Hospitals (8060), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Oncology Telemedicine Platforms (HLALAGAH), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL)

Keywords

• Oncology center services
• Personalized cancer medicine
• Molecular tumor diagnostics
• Cancer research networks
• Comprehensive cancer care

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Deutsche Krebshilfe Funding: As a designated Oncology Center of Excellence (Onkologisches Spitzenzentrum), CCC München receives ongoing funding from Deutsche Krebshilfe for cancer research and care coordination.
2. Health Insurance Reimbursement: Standard medical services are reimbursed through statutory and private health insurance under German healthcare system. The §64e SGB V genome sequencing pilot project is funded by statutory health insurance.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Core offering

CCC München operates as a Comprehensive Cancer Center jointly delivering interdisciplinary oncology patient care, molecular diagnostics, and translational research by bridging LMU Klinikum and TUM Klinikum Rechts der Isar. It runs molecular tumor boards, next-generation sequencing diagnostics, immunotherapy adverse event management, genomic sequencing pilot projects, and clinical study coordination for advanced and rare cancer patients. Patient-facing services include second opinions, the Patientenhaus support center, the Infoportal Krebs information platform, and the OnkoTalk podcast.

Product overview

CCC München is a Comprehensive Cancer Center jointly operated by LMU Klinikum and TUM Klinikum Rechts der Isar, bundling expertise in interdisciplinary oncological patient care and research. The center operates a multi-service model consisting of clinical services (molecular tumor board, tumor boards, second opinions), research networks (DNPM, nNGM Lungenkrebs, SERIO registry), patient support facilities (Patientenhaus, Infoportal Krebs, OnkoTalk podcast), and educational programs. The core offering centers on personalized cancer medicine through molecular diagnostics and genomic sequencing, supported by interdisciplinary tumor boards that review complex cases to identify targeted therapy options.

Differentiator

Problem solved

Functional benefit

Brands

• SERIO - Side Effect Registry Immuno-Oncology: An online registry for side effects of immunotherapies (immune-related adverse events), operated in cooperation with the Paul-Ehrlich-Institut.
• nNGM Lungenkrebs - Nationales Netzwerk Genomische Medizin
• Infoportal Krebs
• OnkoTalk Podcast
• DNPM - Deutsches Netzwerk für Personalisierte Medizin
• Patientenhaus

Products and services

• Molekulares Tumorboard (Molecular Tumor Board) Interdisciplinary tumor board that reviews complex cancer cases using molecular diagnostics (NGS-based) to identify personalized therapy options for patients with advanced or rare cancers who have exhausted standard treatments. Uses cross-location video conferencing to connect LMU and TUM sites.
• Interdisziplinäres ToxBoard Monthly interdisciplinary board led by Prof. Dr. med. Heinzerling that discusses complex cases of immune-related adverse events from checkpoint inhibitor therapy.
• nNGM Lungenkrebs (Nationales Netzwerk Genomische Medizin)

Quantifiable outcome

• 30% of Molecular Tumor Board cases now from external referring physicians
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Nationales Netzwerk Genomische Medizin Lungenkrebs (nNGM)coreStrategic or Co-development Partner · 1 April 2018National Network Genomic Medicine Lung Cancer comprises 20 cancer centers providing nationwide access to molecular diagnostics and innovative therapies for advanced lung cancer patients. Funded by Deutsche Krebshilfe since April 2018. CCC München serves as the Munich hub for the network.
• Deutsche Krebshilfe (DKH)coreStrategic or Co-development Partner · 1 September 2014Deutsche Krebshilfe designated CCC München as an Oncology Center of Excellence (Onkologisches Spitzenzentrum) in September 2014, providing ongoing funding and integrating it into the network of 15 German oncology centers. The partnership enables access to cutting-edge diagnostics and therapies and establishes quality standards for cancer care.
• Netzwerk Onkologische Spitzenzentren (CCC-Netzwerk)coreStrategic or Co-development PartnerThe CCC Network, initiated by Deutsche Krebshilfe in 2009, bundles expertise and interactions among oncology excellence centers. Working groups address SOPs, biobanks, psycho-oncology and other topics. The network ensures nationwide quality standards and research coordination.
• Deutsches Konsortium für Translationale Krebsforschung (DKTK)coreStrategic or Co-development PartnerDKTK is a long-term initiative of the Federal Ministry of Education and Research (BMBF), participating states, and DKFZ. Primary goal is discovery, development, testing and application of new personalized oncology strategies through interdisciplinary research bridging basic science and clinic.
• Deutsches Netzwerk für Personalisierte Medizin (DNPM)coreStrategic or Co-development PartnerDNPM is a cooperation of 26 university clinics in Germany dedicated to improving care and quality of life for patients with advanced or rare cancers. The network standardizes personalized medicine processes and shares knowledge across all participating centers including CCC München.
• Organisation of European Cancer Institutes (OECI)minorStrategic or Co-development PartnerOECI is a European Economic Interest Grouping with 123 member cancer centers. Goal is to accelerate multidisciplinary personalized treatment approaches to reduce mortality and ensure equal access to care across Europe. CCC München participates in OECI working groups and cancer mission activities.
• EURACANminorStrategic or Co-development PartnerEURACAN is a virtual network connecting patients and healthcare providers across Europe for rare cancer treatment. These complex and rare cancers require highly specialized treatment and concentrated knowledge that EURACAN facilitates through its platform.
• Bayerisches Zentrum für Krebsforschung (BZKF)coreStrategic or Co-development PartnerBZKF was founded in November 2019 to provide all Bavarian citizens access to best, newest and most innovative cancer therapies regardless of residence. The six Bavarian university hospitals (Augsburg, Erlangen, Munich 2x, Regensburg, Würzburg) are united to bundle competencies in early detection, therapy and aftercare.
• Bayerische Krebsgesellschaft e.V.minorStrategic or Co-development PartnerBayerische Krebsgesellschaft supports cancer patients and relatives with counseling services and information. Partner in Patientenhaus consortium and awards annual Krebspatientenpreis recognizing outstanding patient communication projects.
• lebensmut e.V.minorStrategic or Co-development Partnerlebensmut supports cancer patients and their families at LMU Klinikum through psychosocial support services. Key partner in Patientenhaus consortium providing holistic support combining high-performance medicine with humanity.
• Eat What You Need e.V.minorStrategic or Co-development PartnerNon-profit alliance for needs-based nutrition in cancer care. Developed was-essen-bei-krebs.de digital platform in partnership with CCC MünchenLMU, providing scientifically-grounded nutrition information for cancer patients.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• European Institute of Oncology (IEO): Italian private comprehensive cancer center in Milan, OECI member. Comparable academic-style CCC focused on personalized oncology and clinical research; broader incumbent in the same category.
• Karolinska Comprehensive Cancer Center: Swedish comprehensive cancer center at Karolinska University Hospital, OECI member. Comparable European academic CCC delivering molecular tumor boards, genomic medicine, and integrated oncology services.
• Gustave Roussy Institut de Cancérologie: Leading European comprehensive cancer center near Paris and OECI member. Larger, well-established incumbent in the same category; offers overlapping molecular tumor board, clinical trial, and translational capabilities and is a reference standard for European CCCs.

Others

• Vivantes Netzwerk für Gesundheit: Berlin-based public hospital network providing oncology services across multiple sites. Adjacent ecosystem participant rather than direct CCC peer; illustrates the public hospital system context in which CCC München operates.

Direct peers

• Comprehensive Cancer Center Erlangen-EMN (CCC Erlangen): DKH Spitzenzentrum at Universitätsklinikum Erlangen, member of BZKF alongside CCC München. Direct peer providing comparable molecular diagnostics and clinical trial services in Bavaria.
• Charité Comprehensive Cancer Center (CCCC) Berlin: Comprehensive Cancer Center at Charité – Universitätsmedizin Berlin, part of the same DKH Spitzenzentren network. Direct peer offering molecular tumor boards, nNGM lung cancer site, and integrated cancer care with strong research output.
• Bayerisches Zentrum für Krebsforschung (BZKF): Bavarian Cancer Research Center founded 2019 by all six Bavarian university hospitals, including CCC München. Operates as an umbrella network — CCC München is both a member and the Munich coordinator, making it a structural peer and collaborator.
• Westdeutsches Tumorzentrum (WTZ) Essen: Consortium-based DKH Spitzenzentrum in North Rhine-Westphalia linking University Hospital Essen and partners. Comparable in delivering nNGM and DNPM services across a multi-hospital structure.
• Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg: DKH-funded Oncology Center of Excellence jointly run by DKFZ and Heidelberg University Hospital; one of the leading German CCCs and a direct peer in DKH's 14-center Spitzenzentren network. Comparable in translational cancer research, MTB operations, and personalized oncology programs.
• Universitäres Cancer Center Hamburg (UCCH): DKH Spitzenzentrum at University Medical Center Hamburg-Eppendorf and University of Hamburg. Comparable comprehensive cancer center offering molecular diagnostics, clinical trials, and integrated oncology care.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks4 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=2wtOKyUcu-s
• LinkedInlinkedin.com/company/ccc-m%C3%BCnchen-comprehensive-cancer-center-m%C3%BCnchen

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CCC München - Comprehensive Cancer Center München